Educational Barriers Are Still Holding Back Biosimilars
Experts Shared Views On Biosimilar Uptake At A Sandoz Webinar
Panellists at a recent webinar hosted by Sandoz on “unlocking the potential of biosimilars” agreed that biologics are increasingly advancing to first-line treatments. However, industry and regulatory leaders cited lack of education as a significant barrier to biosimilars uptake. The experts also offered reasons for the reduced uptake in immunology biosimilars compared to oncology.
